Meropenem: clinical application and production overview of broad-spectrum antibiotics

Meropenem is a β-lactam carbapenem antibiotic with broad-spectrum antibacterial activity and is suitable for the treatment of a variety of serious infections. This article will introduce its pharmacological properties, indications, precautions for use and major manufacturers, focusing on analyzing its key role and safety in clinical practice.

Pharmacological properties and antibacterial spectrum

Meropenem exerts a bactericidal effect by inhibiting bacterial cell wall synthesis and is effective against Gram-positive bacteria, Gram-negative bacteria (including ESBLs-producing strains) and anaerobic bacteria. Its stability is superior to similar drugs and is not easily degraded by renal dehydropeptidase, so there is no need to combine enzyme inhibitors. It is commonly used clinically for severe cases such as pneumonia, abdominal infection, and sepsis. It is especially regarded as one of the "last line of defense" drugs in cases of multi-drug-resistant bacterial infections.

Indications and clinical use points

The indications of meropenem include complicated urinary tract infections, meningitis (the dosage needs to be adjusted to penetrate the blood-brain barrier), and neutropenia accompanied by fever. Must be strictly followed when usingDosage individualizationIn principle, patients with renal insufficiency need to adjust the dosing interval. Common adverse reactions include diarrhea, rash, and occasionally seizures (related to central nervous system permeability), so patients need to be monitored for neurological symptoms.

Manufacturer and market overview

Globally, meropenem is mainly produced by the following companies:

Summary and suggestions for rational medication use

Meropenem is an important choice for the treatment of severe infections, and the indications for use need to be strictly controlled to avoid the development of drug resistance. Clinicians should formulate a plan based on drug susceptibility results and patient status, and pay attention to differences in quality standards of manufacturers. Its efficacy and safety have been confirmed by multiple studies, such as the clear recommendation in the treatment guidelines for drug-resistant bacteria published by the New England Journal of Medicine in 2015 (citation source 1). Rational use of carbapenem antibiotics is critical to curbing the global drug resistance crisis.

Quote sources:
1. "New England Journal of Medicine" 2015 Carbapenem Medication Guidelines
2. National Medical Products Administration (NMPA) meropenem instructions filing data
3. World Health Organization (WHO) Model List of Essential Medicines (2021 Edition)